Promising combo targets tough blood cancer before transplant

NCT ID NCT04566887

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding the targeted drug acalabrutinib to standard R-CHOP chemotherapy improves outcomes for people with untreated mantle cell lymphoma. About 105 participants will receive the combination, then some will proceed to stem cell transplant. The study measures how many achieve complete remission and how long the disease stays controlled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib (a targeted cancer drug) combined with R-CHOP chemotherapy
What this could lead to: If successful, this combination could become a new standard first treatment for mantle cell lymphoma, potentially improving remission rates and long-term control.
What could go wrong: This is an early-phase, non-randomized trial with only 105 participants. Results may not apply to all patients, and side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

BC Cancer Agency

Vancouver, British Columbia, V5Z 4E6, Canada
Centre Hospitalier Universitaire de Québec

Québec, Quebec, G1J 1Z4, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, Canada
QEII Health Sciences Centre

Halifax, Nova Scotia, B3H 2Y9, Canada
Sunnybrook Research Institute

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.